Biomea Fusion Inc (BMEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomea Fusion Inc (BMEA) has a cash flow conversion efficiency ratio of -0.623x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.67 Million) by net assets ($18.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Biomea Fusion Inc worth for the company's overall valuation and market capitalisation.
Biomea Fusion Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Biomea Fusion Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biomea Fusion Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomea Fusion Inc ranked by their cash flow conversion efficiency. Explore Biomea Fusion Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Drilling Tools International Corp.
NASDAQ:DTI
|
-0.026x |
|
DeFi Development Corp.
NASDAQ:DFDV
|
-0.963x |
|
Tomer Energy Royalties 2012 Ltd
TA:TOEN
|
0.021x |
|
Veritone Inc
NASDAQ:VERI
|
-0.281x |
|
Transart Graphics Co Ltd
TW:8481
|
0.021x |
|
RF Industries Ltd
NASDAQ:RFIL
|
-0.025x |
|
Pathfinder Bancorp Inc
NASDAQ:PBHC
|
0.020x |
|
JLK Inc
KQ:322510
|
-0.056x |
Annual Cash Flow Conversion Efficiency for Biomea Fusion Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Biomea Fusion Inc from 2019 to 2025. View Biomea Fusion Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $29.55 Million | $-70.37 Million | -2.381x | -2.43% |
| 2024-12-31 | $51.57 Million | $-119.89 Million | -2.325x | -307.31% |
| 2023-12-31 | $169.24 Million | $-96.59 Million | -0.571x | +0.75% |
| 2022-12-31 | $108.54 Million | $-62.42 Million | -0.575x | -190.12% |
| 2021-12-31 | $178.78 Million | $-35.44 Million | -0.198x | +77.02% |
| 2020-12-31 | $5.17 Million | $-4.46 Million | -0.863x | -101.42% |
| 2019-12-31 | $-21.00K | $-1.28 Million | 60.905x | -- |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase I… Read more